
A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies

Alpha Trial Link:

<https://clinicaltrials.gov/ct2/show/NCT03088878?term=NCT03420183&rank=1>

Alpha Clinic (primary):

UC Davis

Contact:

Name:

Jane McCluskey

Phone:

916-703-9302

Email:

jmccluskey@ucdavis.edu

Alpha Trial Sponsor:

UC Davis

Disease Indication:

B-Cell Leukemia

Enrollment Status:

Recruiting

Source URL: <https://www.cirm.ca.gov/alphaclinictrial/phase-1b-2-study-ror1-targeting-monoclonal-antibody-cirmtuzumab-and-bruton-tyrosine>